Lazabemide

Lazabemide
Systematic (IUPAC) name
N-(2-aminoethyl)-5-chloro-pyridine-2-carboxamide
Clinical data
Routes of
administration
Oral
Legal status
  • (Prescription only)
Identifiers
CAS Number 103878-84-8
ATC code none
PubChem CID 71307
IUPHAR/BPS 6640
ChemSpider 64426
UNII 420HD787N9 YesY
KEGG D04681
Chemical data
Formula C8H10ClN3O
Molar mass 199.64 g/mol

Lazabemide (proposed trade names Pakio, Tempium) is a reversible and selective inhibitor of monoamine oxidase B (MAO-B) that was under development as an antiparkinsonian agent but was never marketed.[1]

References

  1. Henriot S, Kuhn C, Kettler R, Da Prada M. (1994). "Lazabemide (Ro 19-6327), a reversible and highly sensitive MAO-B inhibitor: preclinical and clinical findings.". J Neural Transm Suppl. 41: 321–325. PMID 7931245.



This article is issued from Wikipedia - version of the Tuesday, March 22, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.